Confirmatory Phase III study of Nasodine Nasal Spray (povidone-iodine 0.5%) as a symptomatic treatment for early stage common cold in the natural setting.
Virucidal pilot study of Nasodine® (povidone-iodine 0.5%) nasal spray in people in South Africa with COVID-19 and confirmed nasal shedding of SARS-CoV-2 virus.
Virucidal pilot study of Nasodine® Antiseptic Nasal Spray (povidone-iodine 0.5%) in people with COVID-19 and confirmed nasal shedding of SARS-CoV-2 virus.
100 项与 Firebrick Pharma Ltd. 相关的临床结果
0 项与 Firebrick Pharma Ltd. 相关的专利(医药)
100 项与 Firebrick Pharma Ltd. 相关的药物交易
100 项与 Firebrick Pharma Ltd. 相关的转化医学